Skip to main content
. 2018 Mar 5;26(2):297–305. doi: 10.3727/096504017X14980882803151

Figure 4.

Figure 4

MEG3 downregulates miR-184 and mitigates the progression of leukemia. HL-60 cells were transfected with the LV-MEG3 and/or miR-184 mimic for 24 h. (A) Matrigel invasion assay. (B) Quantifications of (A). (C) Cell viability was assayed by the CCK-8 kit. (D) Mice were injected intraperitoneally with MEG3 overexpression or scramble HL-60 cells, and the tumor size was measured by ruler at 30 days. (E) Calculation of tumor volume at 6, 12, 18, 24, and 30 days after injection. (G, H) The expressions of MEG3 and miR-184 in tumor tissues were assayed by qRT-PCR. (I) Western blot analysis of PCNA and MMP9 in the tumor tissues. (J) Quantitation of (I). All the experiments were repeated at least three times. *p < 0.05, **p < 0.01 versus scramble. #p < 0.05 versus miR-184 mimic treated alone.